Scholarlink

Background <p>This study aimed to evaluate changes in clinical, functional, and inflammatory parameters in patients with severe eosinophilic asthma receiving benralizumab treatment, to determine clinical remission rates, and to explore factors associated with clinical remission.</p> Methods <p>This retrospective single-center real-world study included 33 patients with severe eosinophilic asthma treated with benralizumab at a tertiary referral center. Demographic characteristics, clinical findings, pulmonary function test results, peripheral blood eosinophil counts, and treatment responses were obtained from medical records. Baseline findings were compared with those obtained after at least 12 months of treatment. Clinical remission was defined as the absence of exacerbations, no maintenance oral corticosteroid use, well-controlled asthma, and stable or improved lung function. Factors associated with clinical remission were evaluated using multivariable Firth’s penalized logistic regression.</p> Results <p>The mean age of the 33 included patients was 54.6 ± 13.8 years, and 60.6% were female. After 12 months of treatment, clinical remission was achieved in 75.8% (25/33) of patients. The proportion of patients with well-controlled asthma increased to 90.9%, while maintenance oral corticosteroid use decreased from 48.5% to 24.2% (<i>p</i> = 0.008). The median annual exacerbation rate decreased from 2 to 0 (<i>p</i> &lt; 0.001). Mean FEV₁ increased from 1514 mL to 2188 mL (+ 674 mL; <i>p</i> &lt; 0.001), and FEV₁ (% predicted) improved from 54.9% to 76.8% (<i>p</i> &lt; 0.001). Peripheral blood eosinophil counts decreased from a median of 720 cells/µL to 0 cells/µL (<i>p</i> &lt; 0.001). In multivariable analysis, lower baseline exacerbation frequency (OR 0.52, 95% CI 0.27–0.91; <i>p</i> = 0.021) and higher baseline FEV₁ (per 100 mL increase; OR 1.27, 95% CI 1.01–1.59; <i>p</i> = 0.037) were associated with clinical remission.</p> Conclusions <p>Benralizumab was associated with high clinical remission rates, substantial reductions in exacerbations, and significant improvements in lung function in patients with severe eosinophilic asthma. Given the limited sample size, the findings from the exploratory multivariable analysis should be interpreted with caution and require confirmation in larger prospective studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月28日

查看全文
  • Melis Yağdıran,
  • Kurtuluş Aksu

摘要

Background

This study aimed to evaluate changes in clinical, functional, and inflammatory parameters in patients with severe eosinophilic asthma receiving benralizumab treatment, to determine clinical remission rates, and to explore factors associated with clinical remission.

Methods

This retrospective single-center real-world study included 33 patients with severe eosinophilic asthma treated with benralizumab at a tertiary referral center. Demographic characteristics, clinical findings, pulmonary function test results, peripheral blood eosinophil counts, and treatment responses were obtained from medical records. Baseline findings were compared with those obtained after at least 12 months of treatment. Clinical remission was defined as the absence of exacerbations, no maintenance oral corticosteroid use, well-controlled asthma, and stable or improved lung function. Factors associated with clinical remission were evaluated using multivariable Firth’s penalized logistic regression.

Results

The mean age of the 33 included patients was 54.6 ± 13.8 years, and 60.6% were female. After 12 months of treatment, clinical remission was achieved in 75.8% (25/33) of patients. The proportion of patients with well-controlled asthma increased to 90.9%, while maintenance oral corticosteroid use decreased from 48.5% to 24.2% (p = 0.008). The median annual exacerbation rate decreased from 2 to 0 (p < 0.001). Mean FEV₁ increased from 1514 mL to 2188 mL (+ 674 mL; p < 0.001), and FEV₁ (% predicted) improved from 54.9% to 76.8% (p < 0.001). Peripheral blood eosinophil counts decreased from a median of 720 cells/µL to 0 cells/µL (p < 0.001). In multivariable analysis, lower baseline exacerbation frequency (OR 0.52, 95% CI 0.27–0.91; p = 0.021) and higher baseline FEV₁ (per 100 mL increase; OR 1.27, 95% CI 1.01–1.59; p = 0.037) were associated with clinical remission.

Conclusions

Benralizumab was associated with high clinical remission rates, substantial reductions in exacerbations, and significant improvements in lung function in patients with severe eosinophilic asthma. Given the limited sample size, the findings from the exploratory multivariable analysis should be interpreted with caution and require confirmation in larger prospective studies.